Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

AbCURE_COPD

Financiado

Antibody mediated clearance of senescent cells for treatment of COPD

Chronic Obstructive Pulmonary Disease (COPD) is a group of chronic diseases characterized by airflow limitations in the lung. COPD is a critical international health problem. It is estimated to affect up to 600 million people wor... ver más

30/04/2020

WEIZMANN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-04-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2017-PoC: ERC-Proof of Concept

I+D

Cerrada hace 7 años

0% 100% 100%

2 Participantes

WEIZMANN

150.00K€ | Lider

J URIACH Y COMPAÑIA

638.60K€ | Participante

Proyectos interesantes

SAF2014-54371-R BIOMARCADORES Y PERFILES CLINICOS PERSONALIZADOS EN LA ENFER... 145K€ Cerrado

RESPIRE Development of the first oral disease-modifying treatment fo... 4M€ Cerrado

CPP2021-008747 Investigación del potencial de nuevas moléculas para el trat... 499K€ Cerrado

BES-2010-037064 EFECTOS PROTECTORES DE COMPONENTES DEL SURFACTANTE PULMONAR... 43K€ Cerrado

CNS2023-144357 Fisiopatología de órganos y sistemas 200K€ Cerrado

SAF2009-07810 EFECTOS PROTECTORES DE COMPONENTES DEL SURFACTANTE PULMONAR... 238K€ Cerrado

Últimas noticias

30-11-2024: Cataluña Gestión For... Se ha cerrado la línea de ayuda pública: Gestión Forestal Sostenible para Inversiones Forestales Productivas para el organismo:

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

Duración del proyecto: 25 meses Fecha Inicio: 2018-03-06
Fecha Fin: 2020-04-30

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Chronic Obstructive Pulmonary Disease (COPD) is a group of chronic diseases characterized by airflow limitations in the lung. COPD is a critical international health problem. It is estimated to affect up to 600 million people worldwide and by 2020 it will become the third most frequent cause of death. In Europe alone, COPD affects up to 10% of people (i.e. more people than breast cancer and diabetes) and it takes the life of around 300,000 Europeans each year. Up to date, COPD has no cure as current treatments fail to halt the long-term decline in lung function. They are only able to delay its progression. Those treatments however, are associated with a variety of side effects some of which can be acute and even life threatening. Thus, COPD remains a disease with a significant unmet medical need. In this project (acronymed AbCURE_COPD) we intend to carry out a set of necessary activities for the evaluation of a potentially groundbreaking approach for treating COPD. Our approach is focusing on antibody-mediated clearance of senescent cells which accumulate in tissues with age and contribute to multiple age-related diseases, including COPD. The goal of the PoC project is two-fold. (1) The first goal is to establish the technical feasibility of our idea by testing the effect of senescence-specific antibodies on COPD development and progression by implementing COPD mouse model we developed. (2) The second goal is to establish the business feasibility of our revolutionary approach by taking the necessary steps towards its commercialization, focusing on the creation of strategic alliances with key private sector companies. We firmly believe that with our approach we can significantly extend the health span and improve the quality of life of COPD patients. Equally important, our approach will pave the way for the development of novel treatment strategies applicable to other age-related diseases, such as osteoarthritis, cardiovascular, and neurodegenerative diseases.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores